Photo: SciTecDaily


The London-based biopharmaceutical giant AstraZeneca signed an agreement with Mexico’s Carlos Slim Foundation on Wednesday, Aug. 12, to produce a covid-19 vaccine in both Mexico and Argentina to be distributed without economic profits throughout Latin America.

The experimental coronavirus vaccine, labled AZD1222, which was licensed by AstraZeneca from the University of Oxford, is currently in large-scale Phase III clinical trials and is considered one of the international frontrunners in the race to produce a viable vaccination against covid-19.

Initially, the nonprofit Slim Foundation — founded by Mexican billionaire Carlos Slim — will produce 150 million doses of the vaccine to be distributed throughout the region, except in Brazil, where AstraZeneca has a pre-existing agreement with the Jair Bolsonaro government to distribute the new medication.

In June, the vaccine entered its final trial in Brazil, with ongoing studies continuing in the United Kingdom and South Africa.

In a press release issued by Grupo Carso, the commercial hub of the Slim family conglomerate, the Carlos Slim Foundation stated that, should the vaccine prove successful, it will begin to be made available throughout the rest of Latin America during the first semester of 2021.

In initial trials conducted in Britain, the vaccine was tolerated and generated strong immune responses in all evaluated participants.

These findings were published in The Lancet medical journal.

In Phase I and Phase II testing, a single dose of the vaccine led to a fourfold increase in antibodies to the covid-19 virus in 95 percent of participants within one month after the vaccination´s applñication..

Moreover, in all the subjects tested, T-cell responses peaked by day 14 and were maintained for at least two months after injection.

…Aug. 12, 2020



Leave a Reply